CRACR2B

Across TCGA pan-cancer cohorts, CRACR2B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CRACR2B data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CRACR2B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CRACR2B expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where CRACR2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.660	0.286	.007	19	view →
LSCC	DFS	Median	II,III,IV	0.876	0.971	.014	4	view →
CCRCC	OS	Tertile	IV	0.961	0.174	.036	3	view →
UCEC	DFS	Median	All	0.961	0.848	.020	2	view →
HNSC	OS	Tertile	II,III,IV	1.000	0.766	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CRACR2B–PDAC (OS)

Open the PDAC breakdown →